Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) after an elongated period of silence has come forward make the announcement regarding the outcome of discussions with both the Pharmaceutical and Medical Devices Agency (PMDA) and the European Medicines Agency (EMA).
According to some reliable sources, the meeting was held in Japan and it was a great move that helped ease tension among the various concerned parties. All the involved parties were focusing mainly of the development of voclosporin.
The new drug was expected to play a major role in facing out the active lupus nephritis (LN). Pursuant to these particular talks, the provider stands out as a firm believer in the fact that the confirmatory data that can arise from a single Phase III clinical trial (AURORA).
Going by a talk by one of the top company officials, the latest completed AURA-LV (AURA) Phase IIb study are expected to go a long way in support of the regulatory submissions in the United States, Europe and Japan.
The Vice President of Quality and Regulatory Affairs at Aurinia, Lawrence D. Mandt has come forward to do some clearing of the air around the matter. While speaking, he brought it out clearly that their interactions with regulators in all three jurisdictions had done much towards helping them access a clear itinerary for Phase III.
In addition, he went ahead to outline that they were committed and at the same time greatly believed in their abilities in executing AURORA in a successful fashion .One might be tempted to ask where the company was getting all this confidence from.
As a matter of fact one needs to focus on the strong points of the company in question. The company’s feedback is something that cannot be taken for a ride in all sheer honesty and information gleaned from the AURA research is actually a major step towards the greatly awaited success.
Indeed, the productive conclusion of these regulatory interactions comes as a real-time showcasing of just how much the high end provider is willing to go towards attaining business success as well as in the development of top solutions for all the customers
Those persons that have been struggling with LN condition now have a reason to smile following the unveiling of the exciting new therapeutic option.
